[Form 4] Nautilus Biotechnolgy, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Nautilus Biotechnology insider purchases increased Sujal Patel's stake. The filing shows the CEO, President, Secretary and a director acquired 116,500 shares on 09/05/2025 at a weighted average price of $0.6742 and 83,500 shares on 09/08/2025 at a weighted average price of $0.683, bringing his reported direct beneficial ownership to 10,341,721 shares. The filing also discloses indirect holdings of 1,814,035 shares held in the Sujal Patel 2020 Children\'s Trust and 5,280,476 shares held by PFV I, LLC, where he is manager. The form was signed by an attorney-in-fact on 09/09/2025.

Positive

• Insider purchases totaling 200,000 shares indicate management is buying stock on the open market
• Transparent reporting of indirect holdings via the 2020 Children\'s Trust and PFV I, LLC clarifies total beneficial ownership
• Reporting person holds a substantial combined position (direct plus indirect holdings exceed 17 million shares)

Negative

• None.

Insights

Financial Analyst

TL;DR: Insider purchases of ~200K shares at ~$0.68 modestly increase CEO stake; transaction sizes are small relative to total holdings.

The purchases are explicit open-market acquisitions totaling 200,000 shares at weighted average prices of $0.6742 and $0.683. While the absolute number of shares is meaningful at the micro level, these transactions raise direct holdings to 10.34 million shares and do not by themselves imply material corporate change. Investors should note the combination of direct and indirect holdings that concentrate ownership but the filing contains no information on intent beyond acquisition details.

Corporate Governance Expert

TL;DR: Reporting is standard and transparent; disclosures identify related trusts and entities, consistent with Section 16 requirements.

The Form 4 properly reports direct acquisitions and discloses indirect beneficial ownership via a revocable trust and an LLC managed by the reporting person. The filing includes weighted average price ranges and offers to supply per-price details to the Commission, which supports compliance and transparency. No departures from reporting norms are evident in the document provided.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Patel Sujal M

(Last) (First) (Middle)

C/O NAUTILUS BIOTECHNOLOGY, INC.

2701 EASTLAKE AVENUE EAST

(Street)

SEATTLE WA 98102

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Nautilus Biotechnology, Inc. [ NAUT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CEO, President, and Secretary

3. Date of Earliest Transaction (Month/Day/Year)
09/05/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/05/2025		P		116,500	A	$0.6742(1)	10,258,221	D
Common Stock	09/08/2025		P		83,500	A	$0.683(2)	10,341,721	D
Common Stock								1,814,035	I	By Sujal Patel 2020 Children's Trust, u/a/d December 3, 2020(3)
Common Stock								5,280,476	I	By PFV I, LLC(4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the weighted average share price of an aggregate total of 116,500 shares purchased in the price range of $0.6547 to $0.6899 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

2. Represents the weighted average share price of an aggregate total of 83,500 shares purchased in the price range of $0.6581 to $0.7145 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

3. Shares held by Sujal Patel 2020 Children's Trust, u/a/d December 3, 2020 (the "Patel Trust"). The reporting person and the reporting person's spouse are the trustees of the Patel Trust.

4. Shares held by PFV I, LLC. The reporting person is the manager of PFV I, LLC.

Remarks:

	/s/ Mathew B. Murphy, as Attorney-in-Fact	09/09/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did Sujal Patel report on Form 4 for NAUT?

The filing reports purchases of 116,500 shares on 09/05/2025 at a weighted average price of $0.6742 and 83,500 shares on 09/08/2025 at a weighted average price of $0.683.

How many Nautilus (NAUT) shares does Sujal Patel beneficially own after these transactions?

The filing shows 10,341,721 shares directly owned following the 09/08/2025 purchase, plus 1,814,035 shares via the Patel Trust and 5,280,476 shares via PFV I, LLC.

What roles does Sujal Patel hold at Nautilus as disclosed in the Form 4?

He is disclosed as CEO, President, Secretary, Director and a 10% owner of the issuer.

Were the share purchases made at a single price?

No. Each reported aggregate purchase is reported as a weighted average price covering purchases within specified ranges; the filer offers to provide per-price details on request.

When was the Form 4 filed and signed?

The Form 4 lists transaction dates of 09/05/2025 and 09/08/2025 and bears a signature by an attorney-in-fact dated 09/09/2025.